MUC5B and neoplasm: Bourgeois-Daigneault et al. demonstrated that the antitumor immune response-inducing properties of MG1 can be further augmented by combination with anti-PD-1 or -CTLA-4 therapy, as the combination therapies induced more robust tumor growth inhibition than did the monotherapy controls [151].